Fintech

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

Prnewswire·April 1, 2026 at 11:35 AM

/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business...

Original Source

Prnewswire — www.prnewswire.com

Related in Fintech

Companies Balance AI Opportunities With Fear of Bubble
PYMNTS
Sona Secures $45 Million for AI Platform Expansion
PYMNTS
Tariffs Reshape Business Strategy One Year Later
PYMNTS
eToro launches crypto trading in New York
The Block

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

Companies Balance AI Opportunities With Fear of Bubble

Sona Secures $45 Million for AI Platform Expansion

Tariffs Reshape Business Strategy One Year Later

eToro launches crypto trading in New York